机构ID,机构名称,公告日期,截止日期,报告年度,合并类型,报表来源,货币资金（元）,以公允价值计量且其变动计入当期损益的金融资产,应收票据,应收账款,预付款项,其他应收款,应收关联公司款,应收利息,应收股利,存货,其中：消耗性生物资产,一年内到期的非流动资产,其他流动资产,流动资产合计,可供出售金融资产,持有至到期投资,长期应收款,长期股权投资,投资性房地产,固定资产,在建工程,工程物资,固定资产清理,生产性生物资产,油气资产,无形资产,开发支出,商誉,长期待摊费用,递延所得税资产,其他非流动资产,非流动资产合计,资产总计,短期借款,以公允价值计量且其变动计入当期损益的金融负债,应付票据,应付账款,预收款项,应付职工薪酬,应交税费,应付利息,应付股利,其他应付款,应付关联公司款,一年内到期的非流动负债,其他流动负债,流动负债合计,长期借款,应付债券,长期应付款,专项应付款,预计负债,递延所得税负债,其他非流动负债,非流动负债合计,负债合计,实收资本（或股本）,资本公积,盈余公积,专项储备,减：库存股,一般风险准备,未分配利润,归属于母公司所有者权益,少数股东权益,外币报表折算价差,非正常经营项目收益调整,所有者权益（或股东权益）合计,负债和所有者（或股东权益）合计,其他综合收益,递延收益-非流动负债,结算备付金,拆出资金,发放贷款及垫款-流动资产,衍生金融资产,应收保费,应收分保账款,应收分保合同准备金,买入返售金融资产,划分为持有待售的资产,发放贷款及垫款-非流动资产,向中央银行借款,吸收存款及同业存放,拆入资金,衍生金融负债,卖出回购金融资产款,应付手续费及佣金,应付分保账款,保险合同准备金,代理买卖证券款,代理承销证券款,划分为持有待售的负债,预计负债-流动负债,递延收益-流动负债,其中：优先股-非流动负债,永续债-非流动负债,长期应付职工薪酬,其他权益工具,其中：优先股-所有者权益,永续债-所有者权益
300630,普利制药,2017-04-28,2017-03-31,2017-03-31,合并本期,定期报告,401037974.51,,2515759,25780706.23,13510345.93,7701039.08,,,,25714119.43,,,8472568.92,484732513.1,,,,,2298773.88,83410580.04,174776974.76,,,,,26822694.77,1270830.16,,,1744160.81,,290324014.42,775056527.52,,,,21989367.6,9399313.0,876095.27,10549774.12,,,4088195.99,,4775000.0,,51677745.98,28330700.0,,20200000.0,21225000,,491257.68,,79888398.08,131566144.06,122117620,397856129.12,21012142.27,,,,102504492.07,643490383.46,,,,643490383.46,775056527.52,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
300630,普利制药,2017-08-19,2017-06-30,2017-06-30,合并本期,定期报告,308382042.81,,4616438,33186397.4,8437290.87,1245041.86,,,,14630540.55,,,39261576.5,409759327.99,,,,,2228470.94,81235282.82,232249166.86,,,,,26521187.74,1270830.16,,,1744160.81,,345249099.33,755008427.32,,,,20576714.86,12561153.56,1759863.21,14073491.14,,,2974935.64,,,,51946158.41,,,20268006.67,16937600,,491257.68,,48050254.75,99996413.16,122117620,388213427.21,21009515.77,,,,123671451.18,655012014.16,,,,655012014.16,755008427.32,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
